Multiple Sclerosis Research Today is a free monthly online journal that collates and summarizes the latest research about Multiple Sclerosis, including details on diagnosis, symptoms, treatment, prognosis.

Volume 4 (2007), Issue 5 (May)

1. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
   Neurology, 68(18): 1524-8. [Abstract] [Full-text]
2. A population-based survey of multiple sclerosis in Shanghai, China.
   Neurology, 68(18): 1495-500. [Abstract] [Full-text]
3. Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS.
   Neurology, 68(18): 1488-94. [Abstract] [Full-text]
4. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.
   Brain, 130: 1235-43. [Abstract] [Full-text]
5. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese.
   Brain, 130: 1206-23. [Abstract] [Full-text]
6. Effect of aerobic training on walking capacity and maximal exercise tolerance in patients with multiple sclerosis: a randomized crossover controlled study.
   Phys Ther, 87(5): 545-55; discussion 555-9. [Abstract] [Full-text]
7. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.
   Brain, 130: 1224-34. [Abstract] [Full-text]
8. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis.
   Brain, 130: 1254-62. [Abstract] [Full-text]
9. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.
   Brain, 130: 1194-205. [Abstract] [Full-text]
10. Women with voiding dysfunction secondary to bladder outlet dyssynergia in the setting of multiple sclerosis do not demonstrate significantly elevated intravesical pressures.
    Urology, 69(5): 893-7. [Abstract] [Full-text]
11. The safety and efficacy of IFN-beta products for the treatment of multiple sclerosis.
    Expert Opin Drug Saf, 6(3): 279-88. [Abstract] [Full-text]
12. Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
    Proc Natl Acad Sci U S A, 104(18): 7558-63. [Abstract] [Full-text]
13. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis.
    Acta Neurol Scand, 115(5): 325-30. [Abstract] [Full-text]
14. Cerebrospinal fluid IgG profiles and oligoclonal bands in Chinese patients with multiple sclerosis.
    Acta Neurol Scand, 115(5): 319-24. [Abstract] [Full-text]
15. Intrathecal polyspecific immune response to neurotropic viruses in multiple sclerosis: a comparative report from Cuban patients.
    Acta Neurol Scand, 115(5): 312-8. [Abstract] [Full-text]
16. Ethnicity-dependent association of HLA DRB1-DQA1-DQB1 alleles in Brazilian multiple sclerosis patients.
    Acta Neurol Scand, 115(5): 306-11. [Abstract] [Full-text]
17. Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis.
    Expert Rev Neurother, 7(5): 547-56. [Abstract] [Full-text]
18. Fampridine-SR for multiple sclerosis and spinal cord injury.
    Expert Rev Neurother, 7(5): 453-61. [Abstract] [Full-text]
19. Remyelination can be extensive in multiple sclerosis despite a long disease course.
    Neuropathol Appl Neurobiol, 33(3): 277-87. [Abstract] [Full-text]
20. Differential release of mast cell mediators and the pathogenesis of inflammation.
    Immunol Rev, 217: 65-78. [Abstract] [Full-text]
21. Using religious services to improve health: findings from a sample of middle-aged and older adults with multiple sclerosis.
    J Aging Health, 19(3): 537-53. [Abstract] [Full-text]
22. Multiple sclerosis-like clinical and magnetic resonance imaging findings in human immunodeficiency virus positive-case.
    Neurologist, 13(3): 154-7. [Abstract] [Full-text]
23. Testosterone treatment in multiple sclerosis: a pilot study.
    Arch Neurol, 64(5): 683-8. [Abstract] [Full-text]
24. Reduced cortical surface area in multiple sclerosis.
    Neurol Res, 29(3): 231-2. [Abstract] [Full-text]
25. A dinucleotide deletion in CD24 confers protection against autoimmune diseases.
    PLoS Genet, 3(4): e49. [Abstract] [Full-text]
26. Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.
    Expert Opin Pharmacother, 8(8): 1103-16. [Abstract] [Full-text]
27. Development and validation of a learning needs assessment scale: a continuing professional education tool for multiple sclerosis specialist nurses.
    J Clin Nurs, 16(6): 1099-108. [Abstract] [Full-text]
28. Meta-analysis of genome-wide linkage studies for multiple sclerosis, using an extended GSMA method.
    Eur J Hum Genet, 15(6): 703-10. [Abstract] [Full-text]
29. Contrasting potential of nitric oxide and peroxynitrite to mediate oligodendrocyte injury in multiple sclerosis.
    Glia, 55(9): 926-34. [Abstract] [Full-text]
30. Prognosis of the individual course of disease--steps in developing a decision support tool for Multiple Sclerosis.
    BMC Med Inform Decis Mak, 7: 11. [Abstract] [Full-text]

© 2004-2010 Multiple Sclerosis Research Today. All Rights Reserved.